Agilent Technologies has completed its acquisition of Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP. Biocare is now part of Agilent's Life Sciences and Diagnostics Markets Group, expanding Agilent's pathology portfolio and its ability to serve customers across clinical and research settings. Agilent expects the deal to be accretive to its top-line growth rate, margin profile, and non-instrument revenue mix in the first year, and to become accretive to earnings per share approximately 12 months after closing. The expected impact on Agilent's fiscal 2026 financials will be provided during the third quarter earnings release.
Agilent Technologies IncAgilent completed the acquisition of Biocare Medical, expected to be accretive to growth, margins, and EPS.